← Back to Search

Antibiotic Stewardship for Pneumonia

N/A

Waitlist Available

Led By Michael Klompas, MD

Research Sponsored by Brigham and Women's Hospital

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

All patients admitted to Brigham and Women's and BWH Faulkner Hospitals and prescribed antibiotics with a stated indication of pneumonia who have a median respiratory rate of ≤20 and oxygen saturation of ≥95% without supplemental oxygen sustained for at least 24 hours.

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up duration of hospitalization, up to 90 days

Awards & highlights

Study Summary

This trial is testing whether an electronic alert or pharmacist outreach can help decrease unnecessary antibiotics prescribed to hospitalized patients for possible pneumonia.

Who is the study for?

This trial is for hospitalized patients at Brigham and Women's and BWH Faulkner Hospitals who are prescribed antibiotics for pneumonia but have normal breathing rates (≤20 breaths/min) and oxygen levels (≥95% without extra oxygen) for over 24 hours. It excludes those with cystic fibrosis, in intensive care, on immunosuppressants, under 18, pregnant, or with certain serious infections.Check my eligibility

What is being tested?

The study aims to reduce unnecessary antibiotic use in possible pneumonia cases by comparing usual care with two strategies: an electronic alert system and direct pharmacist outreach. Patients will be randomly assigned to one of these three approaches.See study design

What are the potential side effects?

Since the interventions involve messaging rather than medications, there are no direct side effects from drugs. However, if reducing antibiotics is not appropriate for some patients, it could potentially lead to inadequate treatment of infections.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have pneumonia, treated at Brigham and Women's or BWH Faulkner, breathe normally, and don't need extra oxygen.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ duration of hospitalization, up to 90 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~duration of hospitalization, up to 90 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and duration of hospitalization, up to 90 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Duration of antibiotics prescribed for pneumonia

Secondary outcome measures

Acute kidney injury (maximum creatinine in the 14-days post-randomization)

Antibiotic-free days in the 30-days post-randomization

C. difficile infections in the 30-days post-randomization

+5 more

Trial Design

3Treatment groups

Experimental Treatment

Active Control

Group I: PharmacistExperimental Treatment1 Intervention

Pharmacists will contact the treating teams of eligible patients to note that the patient's respiratory rate and oxygenation are within the normal range and will advise stopping antibiotics prescribed for possible pneumonia.

Group II: Electronic alertExperimental Treatment1 Intervention

An electronic alert will be displayed within the electronic medical record of eligible patients that notes that the patient's respiratory rate and oxygenation are within the normal range and will advise stopping antibiotics prescribed for possible pneumonia

Group III: Usual careActive Control1 Intervention

Clinical teams will decide on antibiotic duration for patients with possible pneumonia without external prompting

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Brigham and Women's HospitalLead Sponsor

1,611 Previous Clinical Trials

11,468,519 Total Patients Enrolled

7 Trials studying Pneumonia

26,727 Patients Enrolled for Pneumonia

Centers for Disease Control and PreventionFED

875 Previous Clinical Trials

22,475,402 Total Patients Enrolled

14 Trials studying Pneumonia

13,568 Patients Enrolled for Pneumonia

Michael Klompas, MDPrincipal InvestigatorBrigham and Women's Hospital

Media Library

Antibiotic stewardship messaging Clinical Trial Eligibility Overview. Trial Name: NCT05172791 — N/A

Pneumonia Research Study Groups: Usual care, Electronic alert, Pharmacist

Pneumonia Clinical Trial 2023: Antibiotic stewardship messaging Highlights & Side Effects. Trial Name: NCT05172791 — N/A

Antibiotic stewardship messaging 2023 Treatment Timeline for Medical Study. Trial Name: NCT05172791 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment in this trial currently available to participants?

"This particular medical study is not currently looking for patients, as evidenced by the data displayed on clinicaltrials.gov which reports that the trial was first announced on July 11th 2022 and last modified on July 19th 2022. However, 170 other trials are actively recruiting participants at this time."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Decreasing Unnecessary Antibiotics Prescribed for Possible Pneumonia Despite Normal Respiratory Rate and Oxygenation

Michael Klompas, M.D. 2022. "Decreasing Unnecessary Antibiotics Prescribed for Possible Pneumonia Despite Normal Respiratory Rate and Oxygenation". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05172791.